FibroBiologics Inc develops fibroblast-based cell therapies to treat chronic diseases such as degenerative disc disease, multiple sclerosis, and wound healing, leveraging the regenerative properties of fibroblasts as a more effective alternative to stem cells. The company addresses significant unmet medical needs by utilizing fibroblasts to enhance tissue regeneration and immune modulation, potentially extending the functional lifespan of key organs like the thymus and spleen.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic diseases like degenerative disc disease, multiple sclerosis, and non-healing wounds present significant challenges due to limited regenerative capacity and ineffective immune modulation. Current treatments often fail to fully restore tissue function or address the underlying causes of immune dysfunction. Traditional stem cell therapies face challenges in sourcing, culturing, and differentiation, limiting their practical application and scalability.
Solution
FibroBiologics develops fibroblast-based cell therapies as a more practical and effective alternative to stem cells for treating chronic diseases. Their approach leverages the regenerative and immune-modulatory properties of fibroblasts, the most common cell type in the human body, to enhance tissue repair and modulate immune responses. Fibroblasts are easier to source, culture, and differentiate compared to stem cells, offering a scalable platform for cell therapy. These fibroblast-based therapies aim to restore function in key organs like the thymus and spleen, and address conditions such as degenerative disc disease, multiple sclerosis, and chronic wounds.
Target Audience
The primary target audience includes patients suffering from chronic diseases such as degenerative disc disease, multiple sclerosis, and non-healing wounds, as well as clinicians and researchers in regenerative medicine and cell therapy.
Features
- Fibroblast-based cell therapies for tissue regeneration and immune modulation
- Potential substitute for Mesenchymal stem cells (MSCs) in treating Degenerative Disc Disease (DDD)
- Therapies designed to improve and extend the productive life of the thymus and spleen
- Utilizing fibroblasts' natural role in the wound healing process
- Fibroblasts are easier to source, culture, and differentiate compared to stem cells